← Human Trials & Peer-Reviewed Studies
Dehydroepiandrosterone secretion in healthy older men and women: effects of testosterone and growth hormone administration in older men.
Plain-language guide to PMID 16926252 (2006): double-blind randomized controlled trial of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).
Key Facts
- PMID
- 16926252
- Journal
- The Journal of clinical endocrinology and metabolism
- Year
- 2006
- Study type
- Randomized Controlled Trial
- Authors
- Muniyappa R et al. (8 authors)
- DOI
- 10.1210/jc.2006-0867
What This Study Did, in Plain Language
What Was Tested
Researchers studied Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in this randomized controlled trial publication.
Their objective was to evaluate morning DHEAS concentrations and nocturnal DHEA secretory dynamics in healthy older men and women, before and after chronic administration of sex steroid(s) alone, GH alone, sex steroid(s) combined with GH, or placebo alone.
Who Took Part
PubMed indexes the participants as older adults and people over 80, both men and women.
How the Study Was Run
The design is described as randomized, double-blind, placebo-controlled and parallel-group.
Because people in this Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
As a double-blind Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study, the assignments were hidden from both participants and investigators until the end.
Some participants received a placebo instead of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), giving a reference point.
Groups ran in parallel: each of the participants stayed in one arm throughout.
What Was Measured
The subject headings attached to it are Aging, Body Mass Index, Circadian Rhythm, Dehydroepiandrosterone, Dehydroepiandrosterone Sulfate, Estradiol and Hormone Replacement Therapy.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).
Results are reported in around 7 sentences of the abstract; we leave them to the paper itself rather than summarise them.
The publication is from 2006 (The Journal of clinical endocrinology and metabolism), a journal based in United States.
More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.
Our Notes on the Compound
Exogenous HGH, sermorelin & older GHRPs (why they're passed over): Constant levels suppress the body's own GHRH, raise somatostatin and dull pituitary response.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.